DE69330090D1 - Verfahren zur Verwendung von (2-Imitazolin-2-ylamino)-chinoxalindeviraten - Google Patents

Verfahren zur Verwendung von (2-Imitazolin-2-ylamino)-chinoxalindeviraten

Info

Publication number
DE69330090D1
DE69330090D1 DE69330090T DE69330090T DE69330090D1 DE 69330090 D1 DE69330090 D1 DE 69330090D1 DE 69330090 T DE69330090 T DE 69330090T DE 69330090 T DE69330090 T DE 69330090T DE 69330090 D1 DE69330090 D1 DE 69330090D1
Authority
DE
Germany
Prior art keywords
carbon atoms
independently selected
mammal
alkyl radicals
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330090T
Other languages
English (en)
Other versions
DE69330090T2 (de
DE599773T1 (de
Inventor
Charles Gluchowski
E Garst
A Burke
A Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE69330090D1 publication Critical patent/DE69330090D1/de
Publication of DE69330090T2 publication Critical patent/DE69330090T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69330090T 1992-01-13 1993-01-12 Verfahren zur Verwendung von (2-Imitazolin-2-ylamino)-chinoxalindeviraten Expired - Fee Related DE69330090T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/820,329 US5231096A (en) 1989-10-12 1992-01-13 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
PCT/US1993/000264 WO1993013771A1 (en) 1992-01-13 1993-01-12 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

Publications (2)

Publication Number Publication Date
DE69330090D1 true DE69330090D1 (de) 2001-05-10
DE69330090T2 DE69330090T2 (de) 2001-09-20

Family

ID=25230500

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330090T Expired - Fee Related DE69330090T2 (de) 1992-01-13 1993-01-12 Verfahren zur Verwendung von (2-Imitazolin-2-ylamino)-chinoxalindeviraten

Country Status (9)

Country Link
US (1) US5231096A (de)
EP (1) EP0620732B1 (de)
JP (1) JPH07503015A (de)
AT (1) ATE200222T1 (de)
AU (1) AU670064B2 (de)
CA (1) CA2127542C (de)
DE (1) DE69330090T2 (de)
ES (1) ES2157216T3 (de)
WO (1) WO1993013771A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
DE69431880T2 (de) * 1993-10-13 2003-09-18 Allergan Inc Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
DK0736020T3 (da) * 1993-12-17 2000-08-07 Procter & Gamble 6-(2-imidazolinylamino)quinolinforbindelser, der er egnede som alfa-2-adrenoceptoragonister
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
CN1137755A (zh) * 1993-12-17 1996-12-11 普罗克特和甘保尔公司 用作α-2肾上腺素能受体兴奋剂的6-(2-咪唑啉基氨基)喹喔啉化合物
CN1046501C (zh) * 1994-02-08 1999-11-17 阿尔康实验室公司 新型硫脲复合物及制备硝基芳基亚氨基杂环的方法
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
NZ504707A (en) 1997-11-24 2002-11-26 Procter & Gamble 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
EP2113246B1 (de) * 2003-08-07 2016-06-22 Allergan, Inc. Zusammensetzungen zur Abgabe von Therapeutika in die Augen und Verfahren zu ihrer Herstellung und Verwendung
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure

Also Published As

Publication number Publication date
EP0620732B1 (de) 2001-04-04
DE69330090T2 (de) 2001-09-20
AU3470093A (en) 1993-08-03
CA2127542A1 (en) 1993-07-22
US5231096A (en) 1993-07-27
EP0620732A1 (de) 1994-10-26
WO1993013771A1 (en) 1993-07-22
ES2157216T3 (es) 2001-08-16
JPH07503015A (ja) 1995-03-30
AU670064B2 (en) 1996-07-04
CA2127542C (en) 2004-08-03
ATE200222T1 (de) 2001-04-15

Similar Documents

Publication Publication Date Title
CA2173974A1 (en) Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
DE69330090T2 (de) Verfahren zur Verwendung von (2-Imitazolin-2-ylamino)-chinoxalindeviraten
ES2063289T3 (es) (2-imidazolin-2-ilamino) tetrahidroquinoxalinas y metodos para usarlas.
EP0549594A4 (de) (2-imidazolin-2-ylamino)chinoxalinderivate und methoden in ihrer anwendung.
DE69426423T2 (de) NEUE HEMMER VON URIDINPHOSPHORYLASE (UrdPase) UND DIHYDROURACILDEHYDROGENASE (DHUDase)
NO923199L (no) Terapeutiske forbindelser
DE69209128D1 (de) Verwendung von Indazol-Methoxyalkansäure zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten
DK0609336T3 (da) Anvendelse af prostacyclin-derivater til forebyggelse eller behandling af lidelser i mikrocirkulationssystemet ved administ
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
NO923413D0 (no) Terapeutiske benzazepin-forbindelser
LU90791I2 (fr) Potentialisateur d'effets antineoplasique et agent antineoplasique
DE69206607D1 (de) Behandlung von kognitiven störungen.
NO923198L (no) Terapeutiske midler
ATE32072T1 (de) Substituierte isochinolinderivate, verfahren zu deren herstellung sowie arzneimittel enthaltend diese verbindungen.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee